Tirzepatide Lowers 10‑Year Predicted Risk of Cardiovascular Disease and Type 2 Diabetes in Adults with Obesity and Prediabetes: Post hoc Analysis of SURMOUNT‑1
Posted inCardiology Diabetes & Endocrinology news

Tirzepatide Lowers 10‑Year Predicted Risk of Cardiovascular Disease and Type 2 Diabetes in Adults with Obesity and Prediabetes: Post hoc Analysis of SURMOUNT‑1

A post hoc analysis of the three‑year SURMOUNT‑1 trial found that once‑weekly tirzepatide (5–15 mg) produced dose‑dependent reductions in 10‑year predicted risks for ASCVD, heart failure, total CVD and progression to type 2 diabetes versus placebo in adults with obesity and prediabetes.
Tirzepatide Produces Large Real‑World Weight Loss in Women with PCOS
Posted inDiabetes & Endocrinology news

Tirzepatide Produces Large Real‑World Weight Loss in Women with PCOS

A large retrospective real‑world cohort (n=4241) of women with PCOS and overweight/obesity treated with tirzepatide experienced mean 18.8% weight loss at 10 months (90% lost ≥10%); digital engagement amplified outcomes. The data are promising but require randomized, biomarker‑driven studies to define metabolic and reproductive benefits and safety in this population.
Obesity Alters Symptom Trajectory and Inflammatory Signatures after Sport-Related Concussion: the NCAA‑DoD CARE Consortium
Posted inDiabetes & Endocrinology Neurology news

Obesity Alters Symptom Trajectory and Inflammatory Signatures after Sport-Related Concussion: the NCAA‑DoD CARE Consortium

In a large prospective cohort, obese BMI (≥30) was associated with worse post-concussion neurocognitive outcomes and a persistently proinflammatory blood biomarker profile, despite fewer baseline symptoms. Findings suggest obesity modifies clinical recovery and biological response after sport-related concussion.
Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence
Posted inDiabetes & Endocrinology Internal Medicine news

Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence

This article critically compares the efficacy, safety, and long-term outcomes of tirzepatide, semaglutide, and liraglutide for the treatment of obesity based on recent Cochrane systematic reviews, highlighting differences in weight loss, adverse events, cardiovascular outcomes, and evidence certainty.
Plant-Based Foods and Their Impact on Metabolic Health and Liver Function in Adults with MASLD and Comorbidities: A Systematic Review
Posted inDiabetes & Endocrinology Gastroenterology news

Plant-Based Foods and Their Impact on Metabolic Health and Liver Function in Adults with MASLD and Comorbidities: A Systematic Review

This systematic review evaluates the effects of specific plant-based foods on metabolic and hepatic outcomes in adults with MASLD and related comorbidities. Findings reveal selective benefits of plant-based dietary components on liver health, glycemic control, and lipid profiles, underscoring potential dietary strategies for MASLD management.
Simultaneous Liver Transplant and Sleeve Gastrectomy: A Dual Approach to Combat Obesity and MASLD with Durable Outcomes
Posted inGastroenterology General Surgery news Transplantation

Simultaneous Liver Transplant and Sleeve Gastrectomy: A Dual Approach to Combat Obesity and MASLD with Durable Outcomes

Combining liver transplant with sleeve gastrectomy yields sustained weight loss, improved metabolic syndrome, and reduced liver allograft steatosis, without increasing mortality or graft loss, offering an effective treatment for obese patients with metabolic dysfunction-associated steatotic liver disease.